Aptevo Therapeutics Operating Income 2014-2022 | APVO

Aptevo Therapeutics operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Aptevo Therapeutics Annual Operating Income
(Millions of US $)
2021 $-21
2020 $-27
2019 $-41
2018 $-52
2017 $-54
2016 $-139
2015 $-61
2014 $-51
2013 $
Aptevo Therapeutics Quarterly Operating Income
(Millions of US $)
2022-03-31 $-6
2021-12-31 $-4
2021-09-30 $-5
2021-06-30 $-6
2021-03-31 $-7
2020-12-31 $-7
2020-09-30 $-6
2020-06-30 $-7
2020-03-31 $-8
2019-12-31 $-8
2019-09-30 $-11
2019-06-30 $-10
2019-03-31 $-11
2018-12-31 $-14
2018-09-30 $-12
2018-06-30 $-12
2018-03-31 $-14
2017-12-31 $-17
2017-09-30 $-10
2017-06-30 $-15
2017-03-31 $-12
2016-12-31 $-22
2016-09-30 $-91
2016-06-30 $-13
2016-03-31 $-13
2015-12-31
2015-09-30 $-13
2015-06-30 $-18
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.018B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00